Drug intelligence / Profile preview

benzalkonium chloride

Development stage: Phase 4
Lead developer: Nippon Kayaku
Modality: Small Molecules
Administration: Topical, Ophthalmic, Intranasal, Vaginal

Overview

Benzalkonium chloride is a quaternary ammonium compound widely utilized as an antiseptic, disinfectant, and preservative in various pharmaceutical and consumer products. Its primary mechanism involves the disruption of cell membranes, leading to broad-spectrum antimicrobial activity. Beyond its preservative and spermicidal applications, benzalkonium chloride is recognized for its potential to induce ocular damage, inflammation, apoptosis, and oxidative stress, particularly when incorporated into ophthalmic formulations. Research often focuses on evaluating its safety profile and mitigating its adverse effects in different therapeutic contexts.

Brand names: Pharmatex
Other names: 苯扎氯胺

Beyond the preview

Go deeper on benzalkonium chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on benzalkonium chloride.

Explore the full profile